Current use of bispecific antibodies to treat multiple myeloma

Targeted immunotherapy has significantly improved the outcome of patients with hematological malignancies by leveraging the power of the ...

Bispecific antibodies in the treatment of multiple myeloma - Nature

The treatment paradigm in myeloma is constantly changing. Upfront use of monoclonal antibodies like daratumumab along with proteasome ...

Bispecific Antibodies for Multiple Myeloma: Six Things Your Patients ...

... treatment of multiple myeloma ... Receive Dana-Farber's e-newsletter, Momentum, to learn of advances in cancer research and care, current clinical ...

Bispecific Therapies | International Myeloma Foundation

Bispecific antibodies (also known as bispecifics, or BsAbs) are an immunotherapy (immune cell therapy) showing promising clinical trial results.

Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance ...

Bispecific antibodies represent a new treatment option for patients with myeloma. These antibodies activate the patient's own T-cells to kill their tumour ...

Dr Chari on Currently Available Bispecific Antibodies in Multiple ...

The first 2 BCMA-targeted bispecific antibodies that were FDA approved for the treatment of patients with multiple myeloma were teclistamab ...

Bispecific Antibody Use in Patients With Lymphoma and Multiple ...

Teclistamab, a B-cell maturation antigen (BCMA) × CD3 BsAb was the first BsAb approved for relapsed or refractory multiple myeloma (RRMM) and ...

Current use of bispecific antibodies to treat mul ti ple mye loma

32 Alto- gether, BCMA and GPRC5D anti gen biallelic or func tional loss are. Figure 2. Mechanisms of resistance to bispecific antibodies in multiple myeloma.

Bispecific Antibodies for Myeloma Treatment

Bispecific antibodies target specific antigens on myeloma cells, with BCMA being the most common, alongside other targets like GPRC5D and FcRH5.

Bispecific Antibody Therapy in Multiple Myeloma - YouTube

Shonali Midha, MD, discusses opportunities for utilizing bispecific antibodies in treating relapsed/refractory multiple myeloma.

Bispecific antibodies in multiple myeloma: revolutionizing blood ...

In addition to applications in MM, BsAbs hold promise as first-in-class therapeutics across various types of solid tumors. Our vision is a world ...

Bispecific Antibodies in Refractory Multiple Myeloma: Basics and ...

In particular, teclistamab, which targets BCMA, has been approved by the FDA for the treatment of relapsed myeloma after 4 lines of therapy.

Current status of bispecific antibodies and CAR-T therapies in ...

Clinical trials of bispecific antibodies against multiple myeloma ... Bispecific antibodies are engineered molecules designed to simultaneously ...

Oncology Nursing Considerations for Bispecific Antibodies in ...

Bispecific antibodies are unique antibody constructs that simultaneously bind 2 antigens, typically targeting an antigen on myeloma cells and a molecule on ...

BCMA- or GPRC5D-targeting bispecific antibodies in multiple ...

Targeted immunotherapies have ushered in a transformative era in multiple myeloma (MM) treatment, with chimeric antigen receptor T cells (CAR T) ...

Current use of bispecific antibodies to treat multiple myeloma

Request PDF | Current use of bispecific antibodies to treat multiple myeloma | Targeted immunotherapy has significantly improved the outcome of patients ...

City of Hope — Developing Bispecific Antibody Therapies to ...

Unlike standard antibody drugs, bispecific antibodies are uniquely engineered to bind to both cancer cells and T cells, engaging T cells to ...

Bispecific Antibodies in Multiple Myeloma: Present and Future

Although more data are needed, bispecifics will likely become an integral part of the multiple myeloma treatment paradigm in the near future.

Current use of bispecific antibodies to treat multiple myeloma.

In multiple myeloma (MM), bispecific T-cell engagers (BsAb) targeting B-cell maturation antigen (BCMA), G protein-coupled receptor, class C, ...

Experts Predict Multiple Myeloma Outcomes Will Improve With ...

Bispecific antibodies have 2 distinct binding domains, which interact with either CD3 on T cells or a tumor-associated antigen on the tumor cell ...